Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Identifieur interne : 001337 ( PubMed/Corpus ); précédent : 001336; suivant : 001338Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Auteurs : Francine Foss ; Barbara Pro ; H. Miles Prince ; Lubomir Sokol ; Dolores Caballero ; Steven Horwitz ; Bertrand CoiffierSource :
- Cancer medicine [ 2045-7634 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic (administration & dosage), Antibiotics, Antineoplastic (therapeutic use), Depsipeptides (administration & dosage), Depsipeptides (therapeutic use), Humans, Lymphoma, T-Cell, Peripheral (drug therapy), Middle Aged, Neoplasm Recurrence, Local (drug therapy), Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibiotics, Antineoplastic, Depsipeptides.
- chemical , therapeutic use : Antibiotics, Antineoplastic, Depsipeptides.
- drug therapy : Lymphoma, T-Cell, Peripheral, Neoplasm Recurrence, Local.
- Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Survival Analysis, Treatment Outcome.
Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.
DOI: 10.1002/cam4.939
PubMed: 27981793
Links to Exploration step
pubmed:27981793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Foss, Francine" sort="Foss, Francine" uniqKey="Foss F" first="Francine" last="Foss">Francine Foss</name><affiliation><nlm:affiliation>Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation><nlm:affiliation>Thomas Jefferson University, Philadelphia, Pennsylvania.</nlm:affiliation></affiliation></author><author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H" last="Miles Prince">H. Miles Prince</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Caballero, Dolores" sort="Caballero, Dolores" uniqKey="Caballero D" first="Dolores" last="Caballero">Dolores Caballero</name><affiliation><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Lyon, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27981793</idno><idno type="pmid">27981793</idno><idno type="doi">10.1002/cam4.939</idno><idno type="wicri:Area/PubMed/Corpus">001337</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001337</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Foss, Francine" sort="Foss, Francine" uniqKey="Foss F" first="Francine" last="Foss">Francine Foss</name><affiliation><nlm:affiliation>Yale Cancer Center, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation><nlm:affiliation>Thomas Jefferson University, Philadelphia, Pennsylvania.</nlm:affiliation></affiliation></author><author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H" last="Miles Prince">H. Miles Prince</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Caballero, Dolores" sort="Caballero, Dolores" uniqKey="Caballero D" first="Dolores" last="Caballero">Dolores Caballero</name><affiliation><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Lyon, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cancer medicine</title><idno type="eISSN">2045-7634</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibiotics, Antineoplastic (administration & dosage)</term><term>Antibiotics, Antineoplastic (therapeutic use)</term><term>Depsipeptides (administration & dosage)</term><term>Depsipeptides (therapeutic use)</term><term>Humans</term><term>Lymphoma, T-Cell, Peripheral (drug therapy)</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Middle Aged</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27981793</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2017</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.</ArticleTitle><Pagination><MedlinePgn>36-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.939</ELocationID><Abstract><AbstractText>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed/refractory PTCL demonstrated an objective response rate of 25% (33/130), including 15% with confirmed/unconfirmed complete response, and a median duration of response of 28 months. In the analysis presented herein, romidepsin was shown to have similar responses and long-term outcomes in patients with 1, 2, and ≥3 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for PTCL irrespective of the number of prior therapies.</AbstractText><CopyrightInformation>© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foss</LastName><ForeName>Francine</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Yale Cancer Center, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pro</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miles Prince</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokol</LastName><ForeName>Lubomir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horwitz</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coiffier</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047630">Depsipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>CX3T89XQBK</RegistryNumber><NameOfSubstance UI="C087123">romidepsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Apr;17(4):1244</RefSource><PMID Version="1">10561185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Aug 10;33(23):2492-9</RefSource><PMID Version="1">26101246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hematol Oncol. 2010 Feb 04;3:5</RefSource><PMID Version="1">20132536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Fundam Clin Pharmacol. 2010 Oct;24(5):547-59</RefSource><PMID Version="1">20584206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Feb 20;30(6):631-6</RefSource><PMID Version="1">22271479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Nutr. 2013 Jul;98(1):160-73</RefSource><PMID Version="1">23719551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2006 Feb 15;107(4):1255-64</RefSource><PMID Version="1">16210342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Jun 15;111(12):5496-504</RefSource><PMID Version="1">18385450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jun 23;117(25):6756-67</RefSource><PMID Version="1">21493798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nephrol Dial Transplant. 2008 Apr;23(4):1415-21</RefSource><PMID Version="1">18065796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Sep 1;26(25):4124-30</RefSource><PMID Version="1">18626005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomark Res. 2014 Sep 08;2:16</RefSource><PMID Version="1">25279222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2015 Jul;170(1):96-109</RefSource><PMID Version="1">25891346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2006 Jun 15;12(12):3762-73</RefSource><PMID Version="1">16778104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2006 Sep;5(9):769-84</RefSource><PMID Version="1">16955068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Chem Biol. 2010 Mar;6(3):238-243</RefSource><PMID Version="1">20139990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiol J. 2011;18(3):233-45</RefSource><PMID Version="1">21660912</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hematol Oncol. 2014 Jan 23;7:11</RefSource><PMID Version="1">24456586</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2014 Oct;40(9):1080-8</RefSource><PMID Version="1">25199959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Oncol. 2007 Sep;19(5):438-43</RefSource><PMID Version="1">17762567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2010 Sep;160(3):464-70</RefSource><PMID Version="1">20826254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jun 20;30(18):2190-6</RefSource><PMID Version="1">22614995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hematol Oncol. 2016 Mar 10;9:22</RefSource><PMID Version="1">26965915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hematol Oncol. 2016 Jul 12;:null</RefSource><PMID Version="1">27402335</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047630" MajorTopicYN="N">Depsipeptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016411" MajorTopicYN="N">Lymphoma, T-Cell, Peripheral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HDAC inhibitor</Keyword><Keyword MajorTopicYN="N">peripheral T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">refractory</Keyword><Keyword MajorTopicYN="N">romidepsin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27981793</ArticleId><ArticleId IdType="doi">10.1002/cam4.939</ArticleId><ArticleId IdType="pmc">PMC5269566</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001337 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001337 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27981793
|texte= Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27981793" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |